Should You Buy, Hold or Sell TLRY Stock Post Q4 Earnings Release?

Tilray Brands reported mixed Q4 FY2025 results, with adjusted EPS of 2 cents beating estimates despite revenue of $224.5 million missing and declining 2% year-over-year; adjusted EBITDA, however, reached $27.6 million, its second-highest ever. For fiscal 2025, total revenues increased 4% to $821 million, largely due to diversification into non-cannabis segments which comprised 70% of sales, offsetting a 9% decline in cannabis revenue. While the company forecasts FY2026 adjusted EBITDA growth of 13-31%, persistent challenges in its core cannabis market and intense competition have contributed to a 56% year-to-date stock decline, leading analysts to suggest a cautious 'Hold' stance.

Analysis

Tilray Brands' fiscal Q4 2025 results present a mixed operational picture, characterized by a strategic pivot away from its struggling core business. While adjusted EPS of 2 cents beat estimates, it marked a 50% year-over-year decline, and quarterly revenues of $224.5 million missed expectations, falling 2% YoY. The core issue remains the cannabis segment, where full-year revenues fell 9% to $249 million due to intense competition and margin pressures in the saturated Canadian market, a decline that a 19% rise in international cannabis sales could not offset. In contrast, the company's diversification strategy is yielding significant results, with non-cannabis segments—beverages, distribution, and wellness—now comprising 70% of total fiscal 2025 sales and driving a 4% increase in full-year revenue to $821 million. The beverage alcohol segment was a standout performer, growing 19% to $240.6 million. Despite these bright spots, the stock's 56% year-to-date plunge, starkly underperforming the industry's 6% growth, reflects investor concern over the deteriorating cannabis fundamentals. The company's guidance for 13-31% adjusted EBITDA growth in fiscal 2026 offers a positive forward-looking metric, but the lack of specific revenue or net income guidance maintains a level of uncertainty.

Key Decisions for Investors

• Investors should re-evaluate Tilray primarily as a consumer-packaged goods company, focusing on the performance of its beverage and wellness divisions, which now drive 70% of revenue, rather than as a pure-play cannabis stock.
• Given the guided 13-31% adjusted EBITDA growth for fiscal 2026, it is critical to monitor the progress of the 'Project 420' cost-saving initiative and its impact on margins, especially in the growing beverage segment.
• Considering the stock's 56% year-to-date underperformance and persistent weakness in the core cannabis business, a hold rating is appropriate; new positions should be considered only after seeing stabilization in cannabis revenues and sustained profitability gains from the diversification strategy.